12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-0752: Phase I/IIa started

Cancer Research UK began an open-label, dose-escalation Phase I/IIa trial of oral MK-0752 plus IV gemcitabine in...

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >